Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Pfizer, inc. symbols : Vygr save search
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Published: 2023-03-07 (Crawled : 12:00) - ir.voyagertherapeutics.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.12%
H: 0.17%
C: -1.75%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 0.63%
H: 0.12%
C: -8.36%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -2.54%
year therapeutics financial results
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
Published: 2022-11-08 (Crawled : 12:20) - ir.voyagertherapeutics.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.11%
H: 1.51%
C: 0.66%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 11.69%
H: 2.44%
C: -1.87%
therapeutics financial results
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Published: 2022-10-04 (Crawled : 11:00) - ir.voyagertherapeutics.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.25%
H: 1.33%
C: 0.47%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 6.57%
H: 13.17%
C: 10.17%
rare disease license therapeutics
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
Published: 2021-11-02 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: -0.95%
H: 7.4%
C: 6.58%
results therapeutics
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Published: 2021-10-06 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.61%
H: 0.33%
C: -0.1%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 61.54%
H: 3.26%
C: -3.01%
cardiovascular gene therapy therapy license cardio aav9 gene therapies aav capsids
Aerovate Therapeutics Announces Second Quarter 2021 Financial Results
Published: 2021-08-16 (Crawled : 12:15) - globenewswire.com
AVTE M | $21.86 1.2% 1.19% 220K
|
Professional, Scientific, and T...
|
| O: -8.86%
H: 4.83%
C: 3.51%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.54%
H: 1.53%
C: 1.41%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: -3.31%
H: 2.05%
C: -1.37%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.56%
H: 0.81%
C: 0.62%
financial results results therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.